Heymach, J., Hanrahan, E., Mann, H., Langmuir, P., Natale, R., Johnson, B., . . . Ryan, A. (2008). Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC.
Chicago Style (17th ed.) CitationHeymach, J., E. Hanrahan, H. Mann, P. Langmuir, R. Natale, B. Johnson, R. Herbst, and A. Ryan. Baseline VEGF as a Potential Predictive Biomarker of Vandetanib Clinical Benefit in Patients with Advanced NSCLC. 2008.
ציטוט MLAHeymach, J., et al. Baseline VEGF as a Potential Predictive Biomarker of Vandetanib Clinical Benefit in Patients with Advanced NSCLC. 2008.
אזהרה: ציטוטים אלה לעיתים לא מדויקים ב 100%.